Does roflumilast induce phagocytic activity in COPD patients?

Figures & data

Table 1 Patients’ characteristics

Characteristics	No % of patients (N=21)
Age, years (mean)	67.4
Sex (male, female)	(86%, 14%)
Groups (C, D)	(72%, 28%)
LABA + ICS + LAMA, LABA + ICS	(28%, 72%)
Frequency of exacerbations (1, 2)	(80%, 20%)
FEV1 % pred (mean)	42.3%
FVC % pred (mean)	63.5%

Abbreviations: LABA, long-acting beta-adrenoceptor agonists; ICS, inhaled corticosteroids; LAMA, long-acting anti-muscarinic agent; pred, predicted; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity.

Figure 1 Mean change of stimulation index (phagocytic activity), FEV₁ % predicted, FVC % predicted, per indicated periods (0: before receiving roflumilast, 3 months and 6 months after).

Notes: Vertical bars represent the 95% confidence intervals of means calculated from analysis of variance error mean square. The pooled standard deviation was used to calculate the intervals.
Abbreviations: pred, predicted; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; CI, confidence interval; stim, stimulation.